Cover Image
市場調查報告書

鞘氨醇-1-磷酸受体1:開發中產品分析

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 386362
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
鞘氨醇-1-磷酸受体1:開發中產品分析 Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 74 Pages
簡介

本報告提供以鞘氨醇-1-磷酸受体1為目標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞與發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鞘氨醇-1-磷酸受体1概要

治療藥的開發

  • 開發中的產品 - 各開發階段
  • 開發中的產品 - 各治療範圍
  • 開發中的產品 - 各適應症

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Actelion Ltd
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG

藥物簡介

暫停中的計劃

主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0966TDB

Summary:

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 4 and 7 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Cardiovascular and Oncology which include indications Multiple Sclerosis, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis, Cardiovascular Disease, Colitis, Crohn's Disease (Regional Enteritis), Dermatological Disorders, Dermatomyositis, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Kidney Transplant Rejection, Primary Biliary Cirrhosis, Relapsing Multiple Sclerosis (RMS) and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • The report reviews Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview
    • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Arena Pharmaceuticals Inc
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Celgene Corp
    • GlaxoSmithKline Plc
    • Idorsia Ltd
    • LG Chem, Ltd.
    • Novartis AG
    • Sanofi
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles
    • AKP-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBP-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenerimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-9531 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etrasimod arginine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FP-253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LC-510255 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIBR-0213 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ozanimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-247799 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products
  • Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones
    • Featured News & Press Releases
      • May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
      • Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis
      • Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
      • Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
      • Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG
      • Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses
      • Oct 11, 2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting
      • Sep 29, 2016: Actelion To Investigate All-Oral Combination Therapy For Patients With Relapsing Multiple Sclerosis
      • Sep 17, 2016: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
      • Sep 16, 2016: Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS
      • Aug 25, 2016: Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
      • Jun 13, 2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
      • May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis
      • Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Actelion Ltd, H2 2017
  • Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Pipeline by Astellas Pharma Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Idorsia Ltd, H2 2017
  • Pipeline by LG Chem, Ltd., H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Sanofi, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top